Emergent BioSolutions Newswire

Emergent BioSolutions Newswire

Comprehensive Real-Time News Feed for Emergent BioSolutions.

Results 1 - 20 of 223 in Emergent BioSolutions

  1. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    4 hrs ago | Business Wire

    ... una partnership stretta con ... IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation of Emergent Biosolutions, Inc. and Advises Investors with Losses to Contact the Firm )--Lundin Law PC announces it is investigating claims against ...

    Comment?

  2. Cholera vaccine developed by University of Maryland wins FDA approvalRead the original story w/Photo

    5 hrs ago | The Baltimore Sun

    ... of poor countries where cholera is endemic because of poor sanitation and a lack of clean water. Emergent BioSolutions, a Gaithersburg-based drug developer, has received a federal task order worth up to $22 million to develop and manufacture a ...

    Comment?

  3. Gaithersburg Company Awarded Contract to Develop Zika VaccineRead the original story w/Photo

    Tuesday | CBS Local

    ... in Gaithersburg has been awarded a contract to develop and manufacture an early-stage Zika vaccine. Emergent BioSolutions said Monday that the base value of the 30-month contract from the Biomedical Advanced Research and Development Authority is ...

    Comment?

  4. Company awarded contract to develop Zika vaccineRead the original story

    Tuesday | Washington Times

    A biopharmaceutical company based in Gaithersburg, Maryland, has been awarded a contract to develop and manufacture an early-stage Zika vaccine. Emergent BioSolutions said Monday that the base value of the 30-month contract from the Biomedical Advanced Research and Development Authority is $17.9 million and it can be extended to $21.9 million.

    Comment?

  5. State, Harford health officials stress prevention as key to stopping Zika virusRead the original story w/Photo

    Tuesday | The Baltimore Sun

    ... Islands, and now the continental U.S., since the current outbreak started in Brazil in late 2015. Emergent BioSolutions, a Gaithersburg-based drug developer, has received a federal task order worth up to $22 million to develop and manufacture a ...

    Comment?

  6. Emergent BioSolutions wins contract to develop Zika vaccineRead the original story w/Photo

    Monday Jun 27 | The Washington Post

    Emergent Biosolutions won a contract to work on a vaccination for the Zika virus, which if approved could be manufactured at their Baltimore facility. Emergent BioSolutions made its name churning out Anthrax vaccines in 2002, after Anthrax-filled envelopes started arriving in the mailboxes of prominent lawmakers.

    Comment?

  7. Emergent BioSolutions nabs Zika contract worth up to $21.9 million from fedsRead the original story w/Photo

    Monday Jun 27 | Business Journal

    Gaithersburg-based Emergent BioSolutions will manufacture one of the first potential vaccines to fight the Zika virus, it announced Monday.

    Comment?

  8. Emergent BioSolutions lands $22 million order to make Zika vaccine candidateRead the original story w/Photo

    Monday Jun 27 | The Baltimore Sun

    Emergent BioSolutions, a Gaithersburg-based drug developer, has received a federal task order worth up to $22 million to manufacture a possible vaccine for Zika virus, the mosquito-borne illness that is a growing threat in the United States. The contract, from the federal Biomedical Advanced Research and Development Authority, calls for Emergent to develop and manufacture Zika vaccine candidates for a Phase 1 clinical trial with humans.

    Comment?

  9. Md. firm lands federal Zika vaccine contractRead the original story

    Monday Jun 27 | Daily Record

    Emergent BioSolutions, a Gaithersburg-based pharmaceutical company, has landed a federal contract of up to $21.9 million to develop and manufacture a vaccine to combat the Zika virus. The Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health & Human Services, will contract with Emergent to use a vaccine candidate provided by ... Complete access to news articles on this website is available to Daily Record subscribers who are logged in.

    Comment?

  10. Emergent Bio nabs BARDA contract to fund development and manufacture Zika vaccineRead the original story w/Photo

    Monday Jun 27 | Seeking Alpha

    Emergent BioSolutions receives a task order from the Biomedical Advanced Research and Development Authority to develop and manufacture three GMP-compliant lots of a Zika vaccine for use in a Phase 1 clinical trial. BARDA will provide the base vaccine candidate while Emergent will conduct technology transfer of process materials and information, process and analytical method development, execute small-scale production runs and perform cGMP cell banking leading to cGMP manufacture of bulk drug substance and final product.

    Comment?

  11. Cowen and Company Downgrades Emergent Biosolutions Inc (EBS) to Market PerformRead the original story w/Photo

    Friday Jun 24 | Daily Political

    A number of institutional investors have recently added to or reduced their stakes in EBS. Eagle Asset Management increased its position in Emergent Biosolutions by 143.9% in the third quarter.

    Comment?

  12. Technavio Announces Top Ten Vendors in the Global Chronic Lymphocytic ...Read the original story

    Thursday Jun 23 | Information Technology

    ... are also entering the market as they foresee huge growth opportunities. Companies such as BioLineRx , Emergent BioSolutions , Infinity Pharmaceuticals , and TG Therapeutics are expected to enter the market during the forecast period. "Vendors are ...

    Comment?

  13. Emergent Biosolutions' (EBS) Buy Rating Reiterated at Wells FargoRead the original story w/Photo

    Thursday Jun 23 | AmericanBankingNews.com

    's stock had its "buy" rating reaffirmed by equities research analysts at Wells Fargo in a report released on Wednesday. Shares of Emergent Biosolutions traded down 2.17% during midday trading on Wednesday, reaching $30.65.

    Comment?

  14. Emergent Biosolutions' (EBS) "Buy" Rating Reaffirmed at Wells FargoRead the original story w/Photo

    Thursday Jun 23 | AmericanBankingNews.com

    ... the stock. Cowen and Company restated a "buy" rating and issued a $40.00 price objective on shares of Emergent Biosolutions in a research report on Friday, February 26th. Singular Research assumed coverage on shares of Emergent Biosolutions in a ...

    Comment?

  15. Why Emergent BioSolutions Inc. Procured a Lower Price TodayRead the original story w/Photo

    Wednesday Jun 22 | Fox News

    What: Emergent BioSolutions is down 19% at 2:40 p.m. EDT after announcing that the U.S. Department of Health and Human Services issued solicitation notices to buy more of its BioThrax anthrax vaccine and potentially NuThrax,Emergent BioSolutions' next-generation anthrax vaccine. So what: The announcement that the company is in the final stages of having a contract in place is good news, but it was widely expected based on conversations Emergent BioSolutions previously had with the Centers for Disease Control and Prevention .

    Comment?

  16. Feds to procure up to 56.4M doses of anthrax vaccines, but only 29.4M ...Read the original story w/Photo

    Wednesday Jun 22 | Seeking Alpha

    Emergent BioSolutions drops on an 8x surge in volume in response to its announcement that the U.S. Department of Health and Human Services has issued two solicitation notices for the continued procurement of 29.4M doses of BioThrax and the advanced development and procurement of up to 27M doses of a next-generation anthrax vaccine, news that appears to disappoint investors. The company believes its next-generation candidate, NuThrax, satisfies the specifications in the HHS solicitation.

    Comment?

  17. U.S. Government Issues Solicitation Notices Providing Path to Achieve ...Read the original story w/Photo

    Wednesday Jun 22 | GlobeNewswire

    Emergent BioSolutions Inc. today announced that on June 21, 2016, the U.S. Department of Health and Human Services issued two solicitation notices with respect to the development and procurement of anthrax vaccines for the Strategic National Stockpile . The company believes that taken together, these two solicitations represent the government's intent to establish and maintain a stockpile of anthrax vaccines capable of protecting 25 million people through the continued procurement of 29.4 million doses of BioThraxA , the only anthrax vaccine licensed by the U.S. Food and Drug Administration , and the advanced development and procurement of up to 27 million dose regimens of a next generation anthrax vaccine.

    Comment?

  18. Emergent BioSolutions Says FDA Accepts Its sBLA For Large-Scale...Read the original story

    Friday Jun 17 | Benzinga

    Emergent BioSolutions Inc. revealed that the Food and Drug Administration has accepted for review its supplemental Biologics License Application seeking approval of the manufacture of BioThrax in Building 55, its large-scale manufacturing facility. According to the company, the regulator set a Prescription Drug User Fee Act target action date of August 15. Emergent BioSolutions' EVP and President biodefense division, Adam Havey, commented, "Emergent's large-scale manufacturing facility, intended to increase the manufacturing capacity for BioThrax to an estimated 20 to 25 million doses annually, is a response to the U.S. government's desire to stockpile 75 million doses of a licensed anthrax vaccine.

    Comment?

  19. FDA Accepts Emergent BioSolutions' Supplemental Biologics License...Read the original story w/Photo

    Friday Jun 17 | GlobeNewswire

    Emergent BioSolutions Inc. today announced that the U.S. Food and Drug Administration has accepted for review Emergent's supplemental Biologics License Application seeking approval of the manufacture of BioThraxA in Building 55, the company's large-scale manufacturing facility. FDA has set a Prescription Drug User Fee Act target action date of August 15, 2016.

    Comment?

  20. Emergent BioSolutions: Underlying Value To Be Realized Following Aptevo Spin-OffRead the original story w/Photo

    Wednesday Jun 1 | Seeking Alpha

    Emergent BioSolutions Inc. is a global specialty pharmaceutical company, which offers specialized products to governments and healthcare providers. The company derives most of its revenue from one product, BioThrax , which is the only FDA-licensed vaccine for the prevention of anthrax disease.

    Comment?